Sequential intravesical gemcitabine-docetaxel vs. bacillus Calmette-Guerin (BCG) in the treatment of non-muscle invasive bladder cancer: A preliminary cost-effectiveness analysis.

MLA

Bukavina, Laura, et al. “Sequential Intravesical Gemcitabine-Docetaxel vs. Bacillus Calmette-Guerin (BCG) in the Treatment of Non-Muscle Invasive Bladder Cancer: A Preliminary Cost-Effectiveness Analysis.” Urologic Oncology, vol. 41, no. 9, Sept. 2023, p. 391.e1-391.e4. EBSCOhost, https://doi.org/10.1016/j.urolonc.2023.04.005.

APA

Bukavina, L., Bell, S., Packiam, V. T., Smaldone, M., Abbosh, P., Uzzo, R., Kutikov, A., Correa, A. F., & Magee, D. E. (2023). Sequential intravesical gemcitabine-docetaxel vs. bacillus Calmette-Guerin (BCG) in the treatment of non-muscle invasive bladder cancer: A preliminary cost-effectiveness analysis. Urologic Oncology, 41(9), 391.e1-391.e4. https://doi.org/10.1016/j.urolonc.2023.04.005

Chicago

Bukavina, Laura, Spencer Bell, Vignesh T Packiam, Marc Smaldone, Philip Abbosh, Robert Uzzo, Alexander Kutikov, Andres F Correa, and Diana E Magee. 2023. “Sequential Intravesical Gemcitabine-Docetaxel vs. Bacillus Calmette-Guerin (BCG) in the Treatment of Non-Muscle Invasive Bladder Cancer: A Preliminary Cost-Effectiveness Analysis.” Urologic Oncology 41 (9): 391.e1-391.e4. doi:10.1016/j.urolonc.2023.04.005.